UnknownNot Applicable

Sonoclot to Evaluate Thrombotic Risk in Proteinuric Pregnancy

United Kingdom13 participantsStarted 2022-03-01

Plain-language summary

There is a lack of consensus on whether women with proteinuric kidney disease benefit from prophylactic anticoagulation during pregnancy to reduce the risk of venous thromboembolism. This pilot study will investigate the feasibility of obtaining thrombosis profile data using a viscoelastic haemostasis monitor - Sonoclot - from pregnant women with kidney disease, and exploratory analyses to elucidate correlations between output values and clinical parameters

Who can participate

Age range18 Years – 55 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed pregnancy by ultrasound scanning or urine or serum beta-HCG * Chronic kidney disease stage 1 to 5, defined as abnormalities of serum creatinine, urine constituents or renal tract anatomy for more than 3 months, or genetic traits associated with renal disease Exclusion Criteria: * Known primary thrombophilia (including factor V Leiden, prothrombin mutations, protein C deficiency, protein S deficiency) * Treatment with low molecular weight heparin in 24 hours prior to consent * Suspected or confirmed active pre-eclampsia or superimposed pre-eclampsia

What they're measuring

Proteinuria (log) to clot time correlation

Timeframe: Through study completion, an average of 9 months

Trial details

NCT IDNCT05108389

SponsorNottingham University Hospitals NHS Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-07-01

View on ClinicalTrials.gov More Pregnancy Complications trials